Mandatory Part 11 Risk Assessment Could Cost Industry Billions

Drug GMP Report
KEYWORDS FDA / Technology

The drug, biologics and device industries could face billions in additional costs if the FDA requires risk analysis to be part of electronic recordkeeping regulations, an industry consultant says.

To View This Article:


Subscribe To Drug GMP Report

Buy This Article Now

Add this article to your cart for $10.00